Evidence map›Paper›PMID 35111680›Full record

ReviewFrontiers in oncology2021

Prospects of Immunotherapy for Triple-Negative Breast Cancer.

Dan Qiu, Guijuan Zhang, Xianxin Yan, Xinqin Xiao, Xinyi Ma, Shujun Lin, Jieyan Wu, Xinyuan Li, Wandi Wang, Junchen Liu and 2 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. The Power and Promise of Patient-Derived Xenografts of Human Breast Cancer.Cold Spring Harbor perspectives in medicine · 2024
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Narrative review on the role of immunotherapy in early triple negative breast cancer: unveiling opportunities and overcoming challenges.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2023
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Dan QiuSchool of Traditional Chinese Medicine of Jinan University, Jinan University, Guangzhou, China.
Guijuan ZhangSchool of Nursing of Jinan University, Jinan University, Guangzhou, China.
Xianxin YanSchool of Traditional Chinese Medicine of Jinan University, Jinan University, Guangzhou, China.
Xinqin XiaoSchool of Traditional Chinese Medicine of Jinan University, Jinan University, Guangzhou, China.
Xinyi MaSchool Public Health, Southern Medical University (No: 3210090112), Guangzhou, China.
Shujun LinSchool of Traditional Chinese Medicine of Jinan University, Jinan University, Guangzhou, China.
Jieyan WuSchool of Traditional Chinese Medicine of Jinan University, Jinan University, Guangzhou, China.
Xinyuan LiSchool of Medicine, Jinan University, Guangzhou, China.
Wandi WangSchool of Medicine, Jinan University, Guangzhou, China.
Junchen LiuSchool of Medicine, Jinan University, Guangzhou, China.
Yi MaDepartment of Cellular Biology, Institute of Biomedicine, National Engineering, Research Center of Genetic Medicine, Key Laboratory of Bioengineering Medicine of Guangdong Province, The National Demonstration Center for Experimental Education of Life Science and Technology, Jinan University, Guangzhou, China.
Min MaSchool of Traditional Chinese Medicine of Jinan University, Jinan University, Guangzhou, China.
Jinan University · CNSouthern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the classification and typing of breast cancer, triple-negative breast cancer (TNBC) is one type of refractory breast cancer, while chemotherapy stays in the traditional treatment methods. However, the impact of chemotherapy is short-lived and may lead to recurrence due to incomplete killing of tumor cells. The occurrence, development, and relapse of breast cancer are relevant to T cell dysfunction, multiplied expression of related immune checkpoint molecules (ICIs) such as programmed death receptor 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) produce immunosuppressive effect. Immunotherapy (namely, immune checkpoint inhibitors, adoptive cellular immunotherapy, CAR-T immunotherapy and some potential treatments) provides new hope in TNBC. This review focuses on the new immune strategies of TNBC patients.

Indexed as

combination therapyCTLA-4immune checkpoint moleculesimmunotherapyPD1/PD-L1 pathwaytriple-negative breast cancers

Identifiers

PMID35111680
PMCPMC8801574
OpenAlexW4205336484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.